The global veterinary reference laboratory market is projected to grow from USD 6.12 billion in 2025 to USD 13.93 billion by 2035, driven by rising pet ownership, pet humanization trends, and increased demand for advanced diagnostics. However, high infrastructure costs and shortage of skilled specialists pose challenges to market expansion.

IDEXX Laboratories reported better-than-expected Q4 2025 earnings of $3.08 per share (beating $2.94 consensus) with $1.091 billion in sales (beating $1.073 billion consensus) and strong growth across segments. The company issued 2026 guidance of $14.29-$14.80 EPS and $4.632-$4.720 billion in sales. Despite the positive results and strong innovation pipeline, IDEXX shares fell 5.57% to $633.10, likely due to guidance slightly below consensus expectations and ongoing end-market visit weakness concerns.

Idexx Laboratories reported strong Q3 2025 financial results, with revenue growing 13% to $1.11 billion and net income rising 18%. The company beat analyst expectations and raised its full-year guidance, leading to a significant stock price increase.

Wall Street opened mixed on Monday, with AI-driven mega-cap stocks rallying while broader markets remained cautious. Nvidia and Amazon saw significant gains, while cryptocurrencies experienced notable declines.

Five S&P 500 stocks outperformed in August 2025, including Albemarle, UnitedHealth Group, Intel, Humana, and Idexx Laboratories, each with unique factors driving their stock price increases.

The veterinary oncology market is projected to grow from $1.84 billion in 2025 to $3.55 billion by 2030, driven by technological advances, rising pet ownership, and increasing demand for advanced cancer treatments in veterinary medicine.

IDEXX Laboratories reported strong Q2 2025 earnings, with $3.50 per share beating estimates and revenue rising 11% to $1.11 billion, driven by robust Companion Animal Group sales. The company raised full-year guidance, reflecting strong performance in pet healthcare.

The global veterinary practice management software market is projected to grow from $818 million in 2024 to $1.3 billion by 2030, with an 8% CAGR, driven by rising pet ownership, digital transformation, and increasing animal health expenditure.

Idexx Laboratories is the global leader in pet healthcare diagnostics, generating substantial recurring revenue from its installed base of diagnostic equipment. Despite its impressive growth and profitability, the company's share price has languished, presenting an opportunity for investors as management ramps up share buybacks at a historically low valuation.

Idexx Laboratories, a leading pet healthcare diagnostics provider, saw its shares rise 9% this week after reporting strong Q4 earnings and providing an optimistic outlook for 2025. The company's razor-and-blades business model, with recurring revenue from consumables and services, has helped it navigate the challenging veterinary industry environment.

The article highlights two S&P 500 stocks, Idexx Laboratories and Zoetis, that have seen significant declines from their all-time highs, presenting a potential once-in-a-decade investment opportunity. The author believes these companies are well-positioned to benefit from the growing pet humanization trend and their respective market-leading positions.

The article discusses the performance of several Nasdaq-100 stocks in October 2024, including Regeneron, Idexx, Moderna, Supermicro, and ASML. It analyzes the reasons behind the price drops and whether any of these stocks present good buying opportunities.